Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.
Clinical Trials
3
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Completed
2
66.7%
Terminated
1
33.3%
No approval data available
- Quantum BioPharma has appointed Dr. Salvatore Napoli, an internationally recognized neurologist with over 20 years of MS experience, as Principal Investigator for its planned Phase 2 clinical trial of Lucid-MS. - The company intends to submit an Investigational New Drug (IND) application to the FDA in the coming weeks for Lucid-MS, a first-in-class neuroprotective compound targeting demyelination in multiple sclerosis. - Lucid-MS is a patented New Chemical Entity that has demonstrated the ability to prevent demyelination in preclinical models, addressing a significant unmet medical need in MS disease progression. - The planned Phase 2 trial will evaluate the efficacy, safety, and tolerability of Lucid-MS in people with multiple sclerosis, pending regulatory clearance from the FDA.
- Quantum BioPharma's unbuzzd dietary supplement demonstrated over 40% faster blood alcohol concentration reduction within 30 minutes compared to placebo in a double-blind, randomized clinical trial. - The study showed statistically significant improvements in alertness, reduced hangover symptoms including 67% reduction in headache severity, and stabilization of heart rate and blood pressure changes from alcohol intoxication. - Published in the World Journal of Pharmaceutical and Medical Research, the trial challenges the long-held belief that alcohol metabolism cannot be significantly accelerated beyond the liver's natural processing rate. - All study participants tolerated unbuzzd well with no reported adverse side effects, marking a potential breakthrough in alcohol recovery supplementation.
- Quantum BioPharma announced a $600 private placement of class A multiple voting shares at $50 per share to fund general working capital purposes. - The company is developing Lucid-MS, a patented new chemical entity that has shown the ability to prevent and reverse myelin degradation in preclinical models of multiple sclerosis. - The financing will be fully subscribed by existing insiders, including CEO Zeeshan Saeed's trust and director Anthony Durkacz's corporation. - Quantum BioPharma maintains a diversified portfolio including neurodegenerative disorder treatments and a 20.11% stake in Unbuzzd Wellness Inc. with royalty agreements.
- Quantum BioPharma and Massachusetts General Hospital have successfully scanned the first multiple sclerosis patient using a novel [18F]3F4AP PET imaging technique designed to monitor demyelination. - The study utilizes a newly installed combined GE Signa PET-MR scanner at MGH that allows simultaneous acquisition of PET and MRI signals, improving spatial and temporal coregistration. - Previous animal and human studies demonstrated that [18F]3F4AP was highly sensitive to demyelinated lesions with favorable pharmacokinetics, suggesting promise as a biomarker for monitoring treatment responses. - The imaging technique may enhance the development of remyelinating and neuroprotective drugs for MS, including Quantum BioPharma's lead compound Lucid-MS.
- Clinical trial demonstrates UnbuzzdTM dietary supplement accelerates alcohol metabolism by 40% within 30 minutes compared to placebo, while improving alertness and stabilizing vital signs. - Study participants reported reduced mental fatigue and hangover symptoms without experiencing adverse side effects, marking a significant advancement in alcohol consumption management. - Quantum BioPharma maintains pharmaceutical development rights while partnering with Celly Nutrition for over-the-counter distribution, securing ongoing royalties up to $250 million.
- Quantum BioPharma's Lucid-21-302, a potential treatment for multiple sclerosis, has progressed to the second cohort dosing phase after positive safety review. - The Phase 1 trial evaluates the safety and pharmacokinetics of Lucid-21-302 in healthy adults, with dosing for the next group expected to begin shortly. - Quantum BioPharma's subsidiary, Lucid Psycheceuticals Inc., focuses on developing Lucid-MS to prevent and reverse myelin degradation in multiple sclerosis. - The company maintains a healthy current ratio of 3.76, indicating a strong ability to meet short-term obligations, and holds significant tax loss carry forwards.
- Quantum Biopharma's Lucid-21-302, a potential oral treatment for multiple sclerosis (MS), has entered a Phase 1 safety and tolerability trial in healthy adults. - The trial aims to assess the safety and pharmacological profile of Lucid-MS, with findings expected to inform the design of a Phase 2 clinical trial in MS patients. - Lucid-MS is designed to protect and potentially repair the myelin sheath, which is damaged in MS, without suppressing the immune system. - Preclinical studies in animal models of MS showed that Lucid-MS restored mobility following paralysis, suggesting potential for functional recovery.
